Ligand Pharmaceuticals Incorporated LGND
Set alert
316.15 USD +9.13 +2.97%
As of Nov 3, 11:16 AM ET
309.46 Day range 317.76
175.89 52-week range 326.63
- YTD
- +67.21%
- 1 year
- +65.31%
- Open
- 309.99
- Prev close
- 307.02
- Mkt cap
- 6.32B
- Vol
- 34.76K
- Avg vol
- 241.59K
- EPS
- 9.49
- P/E
- 33.29
- Div yield
- 0.00%
More statistics
- Low
- 309.46
- High
- 317.76
- Forward P/E
- 25.68
- Beta
- 1.03
- Short ratio
- 9.25
- Inst. own
- 116.12%
- Dividend
- 0.00
- Ex-div date
- Jul 1, 2010
- Earnings
- Feb 25, 2027
- 50-d avg
- 296.39
- 200-d avg
- 252.66
- 1y target
- 350.92
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 350.92 +11.0% upside
Now 316.15
- Target (low)
- 247.00
- Target (mean)
- 350.92
- Target (high)
- 406.00
Ratings (0m) 11 11 buy · 0 hold · 0 sell
- Strong buy3
- Buy8
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 11
- 1 month ago 11
- 2 months ago 10
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | 2.87 | 2.43 – 3.07 | 2.02 | +41.9% | 96.72M | +62.1% | 10 |
| Next quarter | 2.31 | 2.30 – 2.31 | 1.63 | +41.5% | 76.14M | +47.2% | 2 |
| Current year | 9.49 | 9.25 – 9.74 | 8.13 | +16.8% | 291.35M | +8.7% | 10 |
| Next year | 12.21 | 10.51 – 13.46 | 9.49 | +28.6% | 381.00M | +30.8% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Sep 25, 2026 | Barclays | Initiated | — | Overweight |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Citigroup | Maintained | Buy | Buy |
| Aug 14, 2026 | Leerink Partners | Initiated | — | Outperform |
| Aug 7, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Aug 6, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Aug 3, 2026 | Oppenheimer | Reiterated | Outperform | Outperform |
| Jul 15, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Jul 9, 2026 | B of A Securities | Maintained | Buy | Buy |
| Jul 8, 2026 | Stifel | Maintained | Buy | Buy |
| May 8, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 30, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Apr 28, 2026 | RBC Capital | Maintained | Outperform | Outperform |
| Apr 15, 2026 | Citigroup | Maintained | Buy | Buy |
| Apr 14, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 24, 2026 | Citigroup | Maintained | Buy | Buy |
| Mar 11, 2026 | B of A Securities | Initiated | — | Buy |
| Feb 27, 2026 | Oppenheimer | Maintained | Outperform | Outperform |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Dec 10, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Dec 10, 2025 | Stifel | Maintained | Buy | Buy |
| Dec 9, 2025 | Citigroup | Initiated | — | Buy |
| Nov 10, 2025 | RBC Capital | Maintained | Outperform | Outperform |
| Nov 7, 2025 | Benchmark | Maintained | Buy | Buy |
| Nov 7, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Nov 6, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 3, 2025 | Oppenheimer | Maintained | Outperform | Outperform |
| Sep 2, 2025 | Benchmark | Maintained | Buy | Buy |